The role of second-generation 5-HT 3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 59-70

  Schwartzberg, Lee S ^a   Jacobs, Peter ^b,c,d   Matsouka, Panagiota ^e   Azevedo, Wellington ^f   Pinto, Antonio ^g  

^a WEST CLINIC   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF THESSALY   (Greece)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

5HT3 receptor antagonists; Antiemetics; Chemotherapy induced nausea and vomiting; Palonosetron; Stem cell transplantation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLEOMYCIN; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANISETRON; IDARUBICIN; IMATINIB; LENALIDOMIDE; MELPHALAN; METHOTREXATE; ONDANSETRON; PALONOSETRON; PLATINUM COMPLEX; PREDNISONE; PROCARBAZINE; RITUXIMAB; SEROTONIN 3 ANTAGONIST; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVENTION STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; TREATMENT PLANNING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; SALVAGE THERAPY; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; VOMITING;

EID: 84862128456     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.09.005     Document Type: Review

References (58)

1. Hesketh P.J., Kris M.G., Grunberg S.M., et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997, 15:103-109.
2. ASHP Commission on Therapeutics ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999, 56:729-764.
3. Aapro M.S., Molassiotis A., Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005, 13:117-121.
4. Sun C.C., Bodurka D.C., Weaver C.B., et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005, 13:219-227.
5. Lindley C.M., Hirsch J.D., O'Neill C.V., et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992, 1:331-340.
6. O'Brien B.J., Rusthoven J., Rocchi A., et al. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc J 1993, 149:296-302.
7. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000, 18:163-173.
8. Grunberg S.M., Ehler E., McDermed J.E., et al. Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 1988, 80:864-868.
9. Grunberg S.M., Zhang M., Zhang Q., et al. Hospital service use associated with chemotherapy-induced emesis and nausea for patients with principal or secondary diagnosis of cancer. Eur J Cancer 2000, 36(Suppl. 3):S28. Abstract #71.
10. Grunberg S.M., Deuson R.R., Mavros P., et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004, 100:2261-2268.
11. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
12. Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21:4112-4119.
13. Poli-Bigelli S., Rodriques-Pereira J., Carides A.D., et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
14. Schmoll H.J., Aapro M.S., Poli-Bigelli S., et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006, 17:1000-1006.
15. Warr D.G., Hesketh P.J., Gralla R.J., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
16. Van Wijngaarden I., Tulp M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990, 188:301-312.
17. Hesketh P.J., Gandara D.R. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991, 83:613-620.
18. 3 receptors in vitro. Br J Pharmacol 1995, 114:851-859.
19. Rojas C., Stathis M., Thomas A.G., et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008, 107:469-478.
20. Rojas C., Thomas A.G., Alt J., et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010, 626:193-199.
21. Rojas C., Li Y., Zhang J., et al. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010, 335:362-368.
22. Gralla R., Lichinister M., Van Der Vegt S., et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003, 14:1570-1577.
23. Eisenberg P., Figueroa-Vadillo J., Zamora R., et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT-3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003, 98:2473-2482.
24. Aapro M.S., Grunberg S.M., Manikhas G.M., et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006, 17:1441-1449.
25. Saito M., Aogi K., Sekine I., et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009, 10:115-124.
26. 3) palonosetron: an Individual Patient Data (Ipd) meta-analysis and an Abstracted Data (Ad) meta-analysis of the 1947 patients entered into the 8 double-blinded randomized clinical trials (RCTs). Support Care Cancer 2009, 17:872. abstract 02-007.
27. MASCC/ESMO Antiemetic Guidelines 2010. Available through: (accessed February 2011). http://www.mascc.org/.
28. Aapro M., Fabi A., Nolè F., et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for day 1 with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010, 21:1083-1088.
29. Celio L., Frustaci S., Denaro A., et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011, 19(8 (August)):1217-1225.
30. Rodriguez-Abreu D., Bordoni A., Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007, 18(Suppl. 1):i3-i8.
31. American Cancer Society Cancer Facts & Figures 2010. (accessed February 2011). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf.
32. López-Jiménez J., Martín-Ballesteros E., Sureda A., et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006, 91:84-91.
33. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998, 55:173-189.
34. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
35. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. Clin Oncol 2009, 27:1492-1501.
36. Owen J.S., Melhem M., Passarell J.A., et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010, 66:1039-1049.
37. Fernandez H.F. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010, 2010:56-61.
38. Byrd J.C., Ruppert A.S., Mrózek K., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004, 22:1087-1094.
39. Wiernik P.H., Banks P.L., Case D.C., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79:313-319.
40. Lorusso V., Spedicato A., Petrucelli L., et al. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer 2009, 17:1469-1473.
41. Baldomero H., Gratwohl M., Gratwohl A., et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011, 46(4):485-501.
42. Annaloro C., Onida F., Lambertenghi Deliliers G. Autologous hematopoietic stem cell transplantation in autoimmune diseases. Expert Rev Hematol 2009, 2:699-715.
43. Stroncek D.F., Fautsch S.K., Lasky L.C., Hurd D.D., Ramsay N.K., McCullough J. Adverse reactions in patients transfused with cryopreserved marrow. Transfusion (Paris) 1991, 31:521-526.
44. Di Renzo N., Montanini A., Mannina D., et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 2010, [Epub ahead of print].
45. Rigacci L., Landi C., Caruso J.P., et al. Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients. Leuk Res 2011, [Epub ahead of print].
46. Assanelli A.A., Agazzi S., Soliman C., et al. Palonosetron (Aloxi): a single-center experience in the prevention of emesis in patients affected by haematological malignancies. Haematologica 2009, 96(Suppl. 2):187. abstract 0465.
47. Mattiuzzi G.N., Cortes J.E., Blamble D.A., et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010, 116:5659-5666.
48. Musso M., Scalone R., Bonanno V., et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009, 17:205-209.
49. Musso M., Scalone R., Crescimanno A., et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010, 45:123-127.
50. Giralt S.A., Mangan K.F., Maziarz R.T., et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011, 22:939-946.
51. Marcacci G., Becchimanzi C., Arcamone M., et al. Single vs double dose palonosetron for the prevention of acute and delayed nausea and vomiting in patients undergoing high dose chemotherapy and autologous stem cell transplantation. Eur J Cancer 2009, 7(Suppl. 2):574. abstract P-9249.
52. Rzepecki P., Pielichowski W., Oborska S., Barzal J., Mlot B. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. Transpl Proc 2009, 41:3247-3249.
53. Ripaldi M., Parasole R., De Simone G., et al. Palonosetron to prevent nausea and vomiting in children undergoing BMT. Efficacy and safety. Bone Marrow Transplant 2010, 45:1663-1664.
54. Trigg M.E., Inverso D.M. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of anti-emetic regimens. Bone Marrow Transplant 2008, 42:501-506.
55. Walsh T., Morris A.K., Holle L.M., et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind randomized trial. Bone Marrow Transplant 2004, 3:963-968.
56. Paul B., Trovato J.A., Thompson J., et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010, 16:45-51.
57. Egerer G., Eisenlohr K., Gronkowski M., et al. The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010, 70:903-907.
58. Bubalo J.S., Cherala G., McCune J.S., et al. Aprepitant pharmacokinetics and assessing the impact of aprepitant in cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2011, Epub ahead of print.